Role of Maraviroc and/or Rapamycin in Aging Liver Processes

Abstract

Cellular senescence and low-grade inflammation favor the acceleration of aging. The liver is an essential metabolic organ because changes related to its function are related to age-related diseases. The objective of this study was to evaluate the effects of maraviroc (MVC) and/or rapamycin (RAPA) on liver tissue in an experimental model of aging in mice. Eighty male homozygous IL10KO mice were randomly assigned to one of 4 groups (n = 20): i) IL10KO group; ii) MVC group, iii) RAPA group, and iv) MVC-RAPA group. Liver samples were analyzed. Gene expression quantification, western blotting and histopathological analyses were also performed. The proinflammatory cytokines IL-6 and IL-18 were decreased in MVC and MVC/RAPA groups, and TNF-α was decreased in all therapeutic groups. Galactosidase beta-1, was also significantly reduced in all therapeutic groups, as were NK-kB1 and NF-kB2. In all groups, mTOR and CCL5 were significantly reduced. CCR5 expression was decreased in the MVC and MVC/RAPA groups. MVC and RAPA may protect against some factors involved in liver aging. More studies will be necessary to verify their clinical applications.